Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06809595 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
A Phase 3 study of Generalized Anxiety Disorder, sponsored by Definium Therapeutics US.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT06809595 is a Phase 3 study of Generalized Anxiety Disorder that is actively recruiting participants, run by Definium Therapeutics US. The registered enrollment target is 250 participants, above the 210-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (19% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT06809595, a Phase 3 study of Generalized Anxiety Disorder, is actively recruiting participants, sponsored by Definium Therapeutics US.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Panorama
Conditions Studied
Interventions
- OTHER Placebo
- DRUG MM120 (LSD D-Tartrate)
Study Locations (20)
Other
- A-shine s.r.o. - Pilsen
- Institut Neuropsychiatricke Pece (INEP) - Prague
- Psyon s.r.o. - Prague
- Cabinet Dr.Desbonnet : Résidence Saint Michel - Douai
- Hôpital Conception, CIC Centre, bat néphrologie 3eme étage - Marseille
California
- Psychedelic Science Institute - Los Angeles
- West Los Angeles VA Medical Center - Los Angeles
- Cenexel-CNS - Torrance
Florida
- Bradenton Research Center, Inc. - Bradenton
- Clinical Neuroscience Solutions, Inc - Orlando
Ohio
- University of Cincinnati Psychiatry- Anxiety Disorders Research Program - Cincinnati
- Neuro-Behavioral Clinical Research, Inc. - North Canton
Arkansas
- Preferred Research Partners, Inc. - Little Rock
Georgia
- Atlanta Center for Medical Research - Atlanta
Maryland
- Sheppard Pratt Health System - Towson
Massachusetts
- Adams Clinical Boston - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2025-01-29 |
| Est. Completion | 2027-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06809595
The ClinicalTrials.gov registry entry for NCT06809595 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 210-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (19% higher). The listed sponsor is Definium Therapeutics US, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Generalized Anxiety Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06809595 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06809595 about?
NCT06809595 is a clinical study titled "A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)". A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Panorama
What is the current status of trial NCT06809595?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2025-01-29. Estimated completion is 2027-05.
What conditions does trial NCT06809595 study?
This clinical trial studies the following conditions: Generalized Anxiety Disorder.
What interventions are being tested in trial NCT06809595?
The interventions under investigation include: Placebo (OTHER), MM120 (LSD D-Tartrate) (DRUG).
Who is sponsoring clinical trial NCT06809595?
This trial is sponsored by Definium Therapeutics US, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06809595 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Anxiety Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)
RECRUITING · Phase 3
-
A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
COMPLETED · Phase 3
-
Long Term Chamomile Therapy for Anxiety
COMPLETED · Phase 3
-
Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder
COMPLETED · Phase 3
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
-
Neurofeedback Enhanced Cognitive Reappraisal Training - Phase 4
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.